FDA Approval Of Gilead’s Sofosbuvir Shows Flexibility On HCV Combos
This article was originally published in The Pink Sheet Daily
Pricing means an $84,000 cost of therapy for some HCV patients, but $168,000 for others. The nucleotide polymerase inhibitor will be dosed with ribavirin but eliminates interferon for patients with genotypes 2 and 3, making it the first all-oral therapeutic regimen.
You may also be interested in...
New revised draft guidance on HCV drug development recommends that interferon-free regimens, which have become the standard of care, be studied against a direct-acting antiviral comparator.
While Olysio will be priced higher than Incivek for the course of therapy, J&J has a broader strategy for use of the second-generation protease inhibitor. Market analysts are skeptical about the drug’s prospects even though it has some clear edges over the first-generation protease inhibitors for hepatitis C.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.